Modality
ASO
MOA
CAR-T CD19
Target
C5
Pathway
Proteasome
WMIPF
Development Pipeline
Preclinical
~Jul 2016
→ ~Oct 2017
Phase 1
~Jan 2018
→ ~Apr 2019
Phase 2
Jul 2019
→ Jul 2025
Phase 2Current
NCT03366610
487 pts·IPF
2019-07→2025-07·Terminated
487 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-07-198mo agoPh3 Readout· IPF
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
P2/3
Termina…
Catalysts
Ph3 Readout
2025-07-19 · 8mo ago
IPF
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03366610 | Phase 2/3 | IPF | Terminated | 487 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| Elratapinarof | Halozyme | Phase 2 | C5 | |
| HAL-1232 | Halozyme | Approved | C5 | |
| Talasotorasib | Exelixis | Preclinical | APOC3 |